Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Truist Financial Analyst Says

Posted by Brenda Bartman on Oct 30th, 2026

Gilead Sciences logo Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price objective lifted by stock analysts at Truist Financial from $158.00 to $181.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial‘s price target suggests a potential upside of 5.17% from the company’s current price.

A number of other research analysts have also commented on the company. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Jefferies Financial Group reissued a “buy” rating and set a $185.00 price objective on shares of Gilead Sciences in a report on Friday, October 23rd. Barclays dropped their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. HSBC increased their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Finally, Wells Fargo & Company boosted their target price on Gilead Sciences from $165.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $163.96.

Get Our Latest Analysis on GILD

Gilead Sciences Stock Performance

NASDAQ:GILD traded up $6.50 during midday trading on Friday, reaching $172.11. 4,513,284 shares of the company traded hands, compared to its average volume of 6,782,397. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The company has a fifty day moving average price of $150.33 and a 200 day moving average price of $139.55. The firm has a market capitalization of $213.40 billion, a price-to-earnings ratio of -64.56 and a beta of 0.31. Gilead Sciences has a twelve month low of $114.02 and a twelve month high of $175.65.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.19 by $0.36. The firm had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. Gilead Sciences’s quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter last year, the company earned $2.47 EPS. On average, analysts expect that Gilead Sciences will post -0.48 EPS for the current fiscal year.

Insider Activity

In other news, Director Anthony Welters sold 18,000 shares of the business’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the sale, the director directly owned 12,894 shares in the company, valued at approximately $1,916,306.28. The trade was a 58.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the transaction, the director owned 10,066 shares of the company’s stock, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 111,000 shares of company stock valued at $15,877,860. 0.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Persistent Asset Partners Ltd acquired a new stake in Gilead Sciences in the second quarter worth $25,000. Kimelman & Baird LLC bought a new position in shares of Gilead Sciences during the 2nd quarter worth about $25,000. PFS Partners LLC boosted its position in shares of Gilead Sciences by 101.1% during the 3rd quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 96 shares in the last quarter. Laurel Wealth Advisors LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at about $29,000. Finally, Wiser Advisor Group LLC bought a new stake in Gilead Sciences in the 2nd quarter valued at about $30,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: Quarterly results exceeded expectations: Gilead reported third-quarter revenue of $8.3 billion, up 6.8% year over year and approximately $500 million above consensus. Non-GAAP EPS of $2.55 also surpassed estimates of roughly $2.17–$2.19. Gilead Sciences Q3 Earnings and Revenues Top Estimates
Positive Sentiment: 2026 sales outlook was raised: Management now expects full-year product sales of approximately $31.0 billion to $31.3 billion, up from $30.1 billion to $30.4 billion, reflecting strong HIV demand and broader base-business growth. Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength
Positive Sentiment: Growth beyond Biktarvy was encouraging: Trodelvy sales rose 41.7% year over year to $506 million, while management highlighted strong performance across its HIV portfolio. Gilead also agreed to acquire PepStar’s oral IL-23R inhibitor program for $1.275 billion upfront, supporting its future pipeline. Gilead Sciences Why I Remain Bullish After Q3
Positive Sentiment: Analyst support improved: Needham raised its price target to $200 and maintained a Buy rating, while Cantor Fitzgerald increased its target to $175 and kept an Overweight rating after the earnings report. Analysts Increase Forecasts on Gilead Sciences
Neutral Sentiment: Gilead secured a pan-Canadian reimbursement agreement for LYVDELZI, potentially expanding access to the primary biliary cholangitis treatment. The company also declared a quarterly dividend of $0.82 per share.
Negative Sentiment: Longer-term pricing pressure remains: Management said Medicare pricing changes are expected to reduce Biktarvy’s price by about 38% beginning in 2028, creating an estimated $1.5 billion annual revenue headwind. The company also lowered or widened its 2026 EPS outlook, and some analysts cautioned that third-quarter HIV growth benefited from temporary inventory and channel effects. Gilead Hikes 2026 Sales Outlook
Negative Sentiment: Gilead agreed to pay $45 million to settle Texas allegations involving unlawful incentives to healthcare providers, adding a legal and compliance expense.

Gilead Sciences Company Profile

(Get Free Report)

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.